When cancer cells die too fast, they can flood the body with toxins
In short: Killing cancer cells is the goal of treatment, but the speed of that destruction can create a secondary crisis. When tumors break down rapidly, they dump their internal contents into the bloodstream, potentially overwhelming the kidneys and causing a life-threatening medical emergency within hours.
Tumor Lysis Syndrome (TLS) occurs when cancer cells undergo massive lysis, releasing their intracellular contents—specifically potassium, phosphate, and uric acid—into the systemic circulation. While this can happen spontaneously, it most frequently occurs within hours of starting cancer treatments like chemotherapy, steroids, targeted therapy, or immunotherapy. The condition is particularly common in patients with lymphoproliferative malignancies or other fast-growing cancers. Patients with preexisting renal failure face an even higher risk of metabolic derangement. The syndrome can manifest between 12 and 72 hours after a treatment session. It is not a universal side effect, as not every cancer patient will experience it.
The primary danger lies in the kidneys' inability to filter these substances quickly enough. As potassium and phosphate levels spike (hyperkalemia and hyperphosphatemia), they can lead to cardiac arrest or severe electrolyte imbalances. Acute renal failure might occur when calcium phosphate and uric acid crystals settle within renal tubules at the same time. This process is often worsened by lactic acidosis and intravascular volume depletion, creating a dangerous metabolic cycle. The rapid influx of these substances can trigger hypocalcemia as phosphate levels rise. This metabolic crisis is often exacerbated by the presence of lactic acidosis. These complications can turn a successful treatment into a critical emergency.
Medical teams focus on prevention and rapid intervention. Diagnosis involves monitoring blood tests for uric acid, phosphorus, and potassium levels, alongside imaging like CT scans to assess kidney function and ECGs to monitor heart rhythm. Treatment is aggressive, involving intravenous hydration to flush the system, medications like allopurinol or rasburicase to lower uric acid, and occasionally renal replacement therapy (dialysis) to manage the most severe cases. Urinary alkalinization and diuretics are also utilized as part of the management protocol. Rasburicase serves as a safe alternative to allopurinol for preventing uric acid nephropathy. Healthcare providers often perform urinalysis to check for abnormalities in the urine.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Tumour Lysis Syndrome (Tumor Lysis Syndrome) - pathophysiology, diagnosis and treatment
- Also: Tumor Lysis Syndrome (TLS)
- Also: Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome - PubMed
To cite this card, link to https://intellectplus.co.uk/app/science-tumour-lysis-syndrome-tumor-lysis-syndrome-pathophysiology-d.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Science · Latest · A–Z · All topics
